ClinicalTrials.Veeva

Menu

Dietary Proteins: Metagenomic and Metabolomics Approaches for Human Biomarkers Identification

Ö

Örebro University, Sweden

Status

Completed

Conditions

Healthy

Treatments

Dietary Supplement: Protein supplementation

Study type

Interventional

Funder types

Other

Identifiers

NCT05611138
PanProtein 2

Details and patient eligibility

About

This project aims to create a methodological framework, including the discovery and validation of novel biomarker panels to decipher the impact of plant-based protein intake on health biomarkers. Moreover, the possibility of predicting biomarkers production will be tested by a colonic in vitro fermentation study using study participants' faecal samples.

Full description

This study consists of a double-blind, randomised, 3-arm parallel trial, consisting of 2-wk baseline measurements, 4-wk intervention period (with weekly sample collection), and 2-wk after-intervention follow-up, with healthy subjects in each arm consuming different protein sources (from plant- or animal-based sources). Subjects that are eligible to take part in this study will be blinded and randomly allocated to consume an isolated pea protein (arm 1), animal protein (arm 2) or more complex protein pea protein powder (arm 3). The isolated plant and animal protein will be used to evaluate the specific effects of the proteins from the different sources. The more complex protein pea protein powder will be used as a more complex food matrix, containing other food components than protein, to assess how other pea components may impact the specific protein effects. Regardless of the differences in their structure, all supplement powders will be adjusted to provide the same amount of protein. The protein calculation will be done exclusively for each participant, based on their body weight (kg). They will consume up to 2 g of protein per body weight per day. Subjects will be asked to maintain their usual diet and their food intake will be accompanied during the intervention.

Participants' compliance will be followed by their food diaries and by clinical markers for protein intake and will collect blood, faeces and 24 h urine samples. A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge. After the fastening blood sample collection, they will receive the daily protein portion as breakfast. For those, 9 blood sample time points will be taken, being at 0, 15, 30, 60, 90, 120, 150, 180, and 480 min. After the 180 min measurement, they will receive a standard meal as lunch (e.g., pasta with tomato sauce).

Enrollment

59 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18-45 years
  • Body mass index (BMI) 18,5-30 kg/m2
  • Weight stable within the previous 3 months
  • Maintenance of the usual physical activity habits during the study
  • Intake of fibre between 15 and 25 g per day (evaluated by 3 food diaries or 24-hours recalls)
  • Omnivores

Exclusion criteria

  • Acute chronic disease, inflammatory or functional gastrointestinal diseases and any other disease or disorder that could affect the outcome of the study
  • Use of a medication that may interfere the study outcome
  • Eating disorder
  • High protein intake (more than 15% of energy or maximum 1,2 g of protein per kg of body weight per day; evaluated by 3 food diaries or 24-hours recalls)
  • Use of antibiotic medication during the last 3 months prior the first visit
  • Use of antibiotic medication very early in life (e.g., asthmatic children or ear inflammation)
  • Use of laxative or anti-diarrhoea medication within the past 3 months before the study
  • Regular consumption of probiotic or prebiotic product for the past 6 weeks before the study
  • Special diet that is considered to affect the study participation and/or study results, for example, high protein diets
  • More than 5 h of moderate-vigorous exercise per week
  • Pregnancy or breastfeeding
  • Intolerance to dietary supplements that will be used in the study
  • Smoking
  • Abuse of alcohol or drugs

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

59 participants in 3 patient groups

Isolated pea protein
Experimental group
Description:
Dietary supplementation with isolated pea protein powder. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
Treatment:
Dietary Supplement: Protein supplementation
Isolated whey protein
Experimental group
Description:
Dietary supplementation with isolated whey protein. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
Treatment:
Dietary Supplement: Protein supplementation
Concentrated pea protein
Experimental group
Description:
Dietary supplementation with concentrated pea protein Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
Treatment:
Dietary Supplement: Protein supplementation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems